KR102323577B1 - Composition for preventing or treating depression comprising mixed extract of Dioscorea nipponica Makino and Prickly Pear - Google Patents
Composition for preventing or treating depression comprising mixed extract of Dioscorea nipponica Makino and Prickly Pear Download PDFInfo
- Publication number
- KR102323577B1 KR102323577B1 KR1020190166801A KR20190166801A KR102323577B1 KR 102323577 B1 KR102323577 B1 KR 102323577B1 KR 1020190166801 A KR1020190166801 A KR 1020190166801A KR 20190166801 A KR20190166801 A KR 20190166801A KR 102323577 B1 KR102323577 B1 KR 102323577B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- depression
- baeknyeoncho
- fenugreek
- preventing
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 240000001439 Opuntia Species 0.000 title claims description 6
- 235000017008 Dioscorea nipponica Nutrition 0.000 title claims description 5
- 241000908494 Dioscorea nipponica Species 0.000 title claims description 5
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 title claims description 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 64
- 210000004369 blood Anatomy 0.000 claims abstract description 41
- 239000008280 blood Substances 0.000 claims abstract description 41
- 229940076279 serotonin Drugs 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 20
- 208000024891 symptom Diseases 0.000 claims abstract description 19
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 235000020765 fenugreek extract Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 206010054089 Depressive symptom Diseases 0.000 claims description 2
- 206010067371 Menopausal depression Diseases 0.000 claims 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 abstract description 46
- 244000250129 Trigonella foenum graecum Species 0.000 abstract description 46
- 235000001019 trigonella foenum-graecum Nutrition 0.000 abstract description 46
- 239000004480 active ingredient Substances 0.000 abstract description 9
- 238000012423 maintenance Methods 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 5
- 230000035882 stress Effects 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 238000010171 animal model Methods 0.000 description 12
- 208000019901 Anxiety disease Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 239000000935 antidepressant agent Substances 0.000 description 8
- 229940005513 antidepressants Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000009806 oophorectomy Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 229960002464 fluoxetine Drugs 0.000 description 5
- -1 for example Substances 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 206010034912 Phobia Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000219357 Cactaceae Species 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 206010000605 Acrophobia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000507614 Chama Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical class C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940083609 fluoxetine 20 mg Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 208000022084 motor paralysis Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
본 발명은 부채마와 백년초의 혼합추출물을 유효성분으로 포함하는 우울증 예방 또는 치료용 약학 조성물, 상기 약학 조성물을 사용하여 우울증을 치료하는 방법, 부채마와 백년초의 혼합추출물을 유효성분으로 포함하는 우울증 개선용 식품 조성물 및 부채마와 백년초의 혼합추출물을 유효성분으로 포함하는 우울증 개선용 사료 조성물에 관한 것이다. 본 발명에서 제공하는 부채마와 백년초의 혼합추출물을 포함하는 조성물은 우울증에 의한 부동자세 유지시간을 감소시키고, 혈중 세로토닌의 수준을 증가시킬 수 있으며, 혈중 코르티코스테론의 수준을 감소시킬 수 있으므로, 우울증 증상의 개선에 널리 활용될 수 있을 것이다.The present invention relates to a pharmaceutical composition for preventing or treating depression comprising a mixed extract of fenugreek and baeknyeoncho as an active ingredient, a method for treating depression using the pharmaceutical composition, depression comprising a mixed extract of fenugreek and baeknyeoncho as an active ingredient It relates to a food composition for improvement and a feed composition for improving depression comprising a mixed extract of fenugreek and baeknyeoncho as an active ingredient. The composition comprising a mixed extract of fenugreek and baeknyeoncho provided in the present invention can reduce the immobility maintenance time due to depression, increase the level of serotonin in the blood, and reduce the level of corticosterone in the blood, It can be widely used to improve the symptoms of depression.
Description
본 발명은 부채마와 백년초의 혼합추출물을 포함하는 우울증 예방 또는 치료용 조성물에 관한 것으로, 보다 구체적으로 본 발명은 부채마와 백년초의 혼합추출물을 유효성분으로 포함하는 우울증 예방 또는 치료용 약학 조성물, 상기 약학 조성물을 사용하여 우울증을 치료하는 방법, 부채마와 백년초의 혼합추출물을 유효성분으로 포함하는 우울증 개선용 식품 조성물 및 부채마와 백년초의 혼합추출물을 유효성분으로 포함하는 우울증 개선용 사료 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating depression comprising a mixed extract of fenugreek and baeknyeoncho, and more specifically, the present invention relates to a pharmaceutical composition for preventing or treating depression comprising a mixed extract of fenugreek and baeknyeoncho as an active ingredient, A method of treating depression using the pharmaceutical composition, a food composition for alleviating depression comprising a mixed extract of fenugreek and baeknyeoncho as an active ingredient, and a feed composition for improving depression comprising a mixed extract of fenugreek and baeknyeoncho as an active ingredient it's about
우울증은 흔한 정신질환으로 마음의 감기라고도 부르며, 원활하지 못한 대인관계를 야기할 수 있고, 심한 경우 자살이라는 심각한 결과에 이를 수 있는 뇌질환이다. 다행히도 우울증은 효과적으로 치료될 수 있는 질환이며, 초기 완쾌율이 2개월 내에 70~80%에 이르는 의학적 질환이다. 우울증에는 상담과 정신과 치료가 필수적이며 중등도 이상의 우울증은 항우울제 투여도 반드시 필요하다. Depression is a common mental illness, also called a cold of the mind, and is a brain disease that can cause poor interpersonal relationships and, in severe cases, can lead to serious consequences of suicide. Fortunately, depression is a disease that can be effectively treated, and is a medical disease with an initial recovery rate of 70-80% within 2 months. Counseling and psychiatric treatment are essential for depression, and antidepressant administration is also essential for moderate to severe depression.
최근 개발된 항우울제들은 뇌 내의 저하된 세로토닌을 증가시켜 우울 증상을 호전시키고, 부작용이 거의 없이 안전하게 우울증을 개선할 수 있다. 우울증의 원인은 다양한데, 그 중에서 생물학적인 원인이 있는 경우는 뇌의 신경전달물질의 불균형으로 인한 것이다. 대표적인 신경전달 물질의 예로 히스타민, 세로토닌, 도파민 등이 있다. 흔히 세로토닌이라는 뇌 내 신경전달물질의 저하가 우울증과 관련이 높은 것으로 알려져 있다. 또한, 생활 및 환경 스트레스가 원인이 될 수 있는데, 사랑하는 사람의 죽음, 이별, 외로움, 실직, 경제적인 걱정과 같은 스트레스가 우울증을 유발하거나 악화시킬 수 있으며, 신체적인 질환이나 약물 등에 의해 발생할 수 있다. 일례로, 암, 내분비계 질환, 뇌의 혈액순환장애에 의하여 일어나는 급격한 의식장애와 운동마비를 수반하는 뇌졸중 등 다양한 질환이 우울증을 유발할 수 있다. 또한, 갱년기와 같이 나이의 변화에 의하여 신체적인 밸런스가 변화될 경우, 이에 의하여도 우울증이 유발될 수 있다고 알려져 있다.Recently developed antidepressants can improve depressive symptoms by increasing the decreased serotonin in the brain, and can safely improve depression with few side effects. There are various causes of depression, and the biological cause is due to an imbalance of neurotransmitters in the brain. Examples of typical neurotransmitters include histamine, serotonin, and dopamine. It is known that a decrease in a neurotransmitter in the brain called serotonin is often associated with depression. In addition, life and environmental stress can be the cause. Stress such as the death of a loved one, separation, loneliness, job loss, or financial worries can cause or aggravate depression, and can be caused by a physical illness or medication. . For example, various diseases, such as cancer, endocrine disease, and stroke accompanied by a sudden loss of consciousness and motor paralysis caused by a blood circulation disorder in the brain, can cause depression. In addition, it is known that when the physical balance is changed by the change of age, such as menopause, depression can also be induced by this.
불안장애는 다양한 형태의 비정상적, 병적인 불안과 공포로 인하여 일상 생활에 장애를 일으키는 정신 질환을 통칭한다. 불안과 공포는 정상적인 정서 반응이지만, 정상적 범위를 넘어서면 정신적 고통과 신체적 증상을 초래한다. 불안으로 교감신경이 흥분되어 두통, 심장 박동 증가, 호흡수 증가, 위장관계 이상 증상과 같은 신체적 증상이 나타나 불편하고 가정생활, 직장생활, 학업과 같은 일상 활동을 수행하기 어려운 경우 불안장애로 진단할 수 있다. 이러한 불안장애에는 다양한 진단이 있으며, 각각 특징적인 정의와 진단 기준이 마련되어 있다. 불안장애에 해당하는 질환으로는 공황 장애, 특정 공포증(고소 공포증, 혈액 공포증, 뱀 공포증 등), 사회 공포증, 강박 장애, 외상 후 스트레스 장애, 범 불안장애, 급성 스트레스 장애가 포함된다. 불안장애에는 각기 다른 성격의 여러 정신질환이 속해 있어, 복합적이라 원인을 한마디로 규정하기는 어렵다. 일반적으로 불안이나 우울 등의 정서적인 부분을 담당하는 뇌신경 내의 신경전달물질의 부족 또는 과다, 유전적으로 타고난 소인, 뇌영상 연구에서 밝혀진 뇌의 기능적 또는 구조적 변화를 포함하여, 사회심리학적인 측면, 과거의 경험과 현재의 받아들인 정보를 해석하고 판단하는 인지행동적인 부분까지도 병적인 불안을 일으키는 원인이 될 수 있다. 특히 외상 후 스트레스 장애나 급성 스트레스 장애는 극심한 정신적 충격을 일으키는 사고나 재해 등이 원인으로 주로 발병한다.Anxiety disorder is a collective term for mental disorders that cause disturbances in daily life due to various types of abnormal and pathological anxiety and fear. Anxiety and fear are normal emotional responses, but when they go beyond the normal range, they cause mental distress and physical symptoms. Anxiety disorder can be diagnosed when the sympathetic nervous system is excited due to anxiety, causing physical symptoms such as headache, heart rate increase, respiratory rate, and gastrointestinal abnormalities, making it difficult to perform daily activities such as home life, work life, and schoolwork. can There are various diagnoses of these anxiety disorders, and each has a characteristic definition and diagnostic criteria. Anxiety disorders include panic disorder, specific phobias (acrophobia, blood phobia, snake phobia, etc.), social phobia, obsessive compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, and acute stress disorder. Anxiety disorder includes several mental disorders with different personalities, and it is difficult to define the cause in a word because it is complex. In general, lack or excess of neurotransmitters in the cranial nerves, which are responsible for emotional parts such as anxiety or depression, genetic predisposition, social psychological aspects, including functional or structural changes in the brain revealed in brain imaging studies, and past Even the cognitive-behavioral part of interpreting and judging experiences and current received information can cause pathological anxiety. In particular, post-traumatic stress disorder or acute stress disorder is mainly caused by accidents or disasters that cause severe psychological shock.
지금까지 개발된 우울증 치료제는 대부분 화합물을 유효성분으로 포함하는 제제가 개발되었는데, 예를 들어, 프락신을 유효성분으로 포함하는 우울증 치료제(한국등록특허 제10-2021281호), 케타민 유도체를 유효성분으로 포함하는 우울증 치료제(한국공개특허 제10-2019-0120859호) 등이 개발되었다. 그러나, 이들 우울증 치료제는 우울증의 증상 자체는 개선시킬 수 있었으나, 다른 부작용으로 인하여, 실질적인 우울증 치료에 사용하지 못하는 실정이다. 이에 따라, 보다 안전하면서도 효과적으로 우울증을 개선할 수 있는 방법의 개발이 시급한 상황이다.Most of the antidepressants developed so far have been developed formulations containing compounds as active ingredients, for example, antidepressants containing praxin as an active ingredient (Korea Patent No. 10-2021281), and ketamine derivatives as an active ingredient. A treatment for depression including (Korean Patent Publication No. 10-2019-0120859) has been developed. However, these antidepressants were able to improve the symptoms of depression themselves, but due to other side effects, they cannot be used for actual depression treatment. Accordingly, there is an urgent need to develop a safe and effective method for alleviating depression.
이러한 배경하에서, 본 발명자들은 보다 안전하면서도 효과적으로 우울증를 개선할 수 있는 방법을 개발하고자 예의 연구노력한 결과, 부채마와 백년초의 혼합추출물을 마우스 모델에 투여할 경우, 우울증에 의한 다양한 증상을 개선시킬 수 있음을 확인하고, 본 발명을 완성하였다. Under this background, the present inventors have made intensive research efforts to develop a safer and more effective method for alleviating depression. was confirmed, and the present invention was completed.
본 발명의 주된 목적은 부채마와 백년초의 혼합추출물을 포함하는 우울증 예방 또는 치료용 약학 조성물을 제공하는 것이다.The main object of the present invention is to provide a pharmaceutical composition for preventing or treating depression comprising a mixed extract of fenugreek and baeknyeoncho.
본 발명의 다른 목적은 상기 약학 조성물을 사용하여 우울증을 치료하는 방법을 제공하는 것이다.Another object of the present invention is to provide a method for treating depression using the pharmaceutical composition.
본 발명의 또 다른 목적은 부채마와 백년초의 혼합추출물을 포함하는 우울증 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for improving depression comprising a mixed extract of fenugreek and baeknyeoncho.
본 발명의 또 다른 목적은 부채마와 백년초의 혼합추출물을 포함하는 우울증 개선용 사료 조성물을 제공하는 것이다.Another object of the present invention is to provide a feed composition for improving depression comprising a mixed extract of fenugreek and baeknyeoncho.
상술한 목적을 달성하기 위한 본 발명의 일 실시양태는 부채마 추출물과 백년초 추출물의 혼합추출물을 포함하는 우울증 예방 또는 치료용 약학 조성물을 제공한다.One embodiment of the present invention for achieving the above object provides a pharmaceutical composition for preventing or treating depression, comprising a mixed extract of the extract of fenugreek extract and baeknyeoncho extract.
본 발명의 용어 "부채마(Dioscorea nipponica Makino)"란, 마과 식물에 속하는 덩굴성 여러해살이 풀을 의미하는데, 형태적으로 보면 줄기는 길게 옆으로 뻗고, 성글게 가지를 치며, 뿌리줄기는 둥근 통 모양이고, 많은 뿌리를 형성하는 것으로 알려져 있다. 또한, 약학적으로는 뿌리줄기가 효과를 나타낸다고 알려져 있는데, 주로 동맥경화증, 심근경화증, 고지혈증 등의 증상을 치료하는 효과를 나타낸다고 알려져 있다.As used herein, the term " Dioscorea nipponica Makino " refers to a creeping perennial grass belonging to the family Hemiaceae. In terms of morphology, the stem extends long and sideways, branches loosely, and the rhizome has a round tube shape. and is known to form many roots. In addition, it is known that rhizomes are pharmaceutically effective, and are known to mainly exhibit an effect of treating symptoms such as arteriosclerosis, myocardial sclerosis, and hyperlipidemia.
본 발명의 용어 "백년초(Prickly Pear)"란, 선인장과(Cactaceae)의 선인장속(Opuntia)에 속하는 열대성 귀화 식물로 우리나라에서는 제주도, 신안군 등 남해안 지방에 자생하고 있다, 상기 백년초는 가뭄 저항성이 강하고 그 열매는 식용으로 이용할 수 있는것으로 알려져 있는데, 약학적으로는 항궤양 효과, 이뇨 효과, 고혈압 예방 효과, 콜레스테롤 저하 효과, 혈당 저하 효과, 항당뇨 효과, 상처 치유 효과, 항염증 효과, 항산화 효과 등을 나타낸다고 알려져 있다. The term "Prickly Pear " of the present invention is a tropical naturalized plant belonging to the genus Opuntia of the Cactaceae family. Its fruits are known to be edible, and in pharmaceutical terms, anti-ulcer effect, diuretic effect, hypertension prevention effect, cholesterol lowering effect, blood sugar lowering effect, antidiabetic effect, wound healing effect, anti-inflammatory effect, antioxidant effect, etc. is known to represent
본 발명의 용어 "혼합추출물"이란, 본 발명에서 제공하는 부채마 추출물과 백년초 추출물의 혼합물을 의미한다.The term "mixed extract" of the present invention refers to a mixture of the extract of fenugreek and baeknyeoncho extract provided in the present invention.
본 발명에 있어서, 상기 혼합추출물은 각각 수득한 부채마 추출물과 백년초 추출물을 혼합하여 수득할 수도 있고, 부채마와 백년초의 혼합물을 추출하여 수득할 수도 있다.In the present invention, the mixed extract may be obtained by mixing the obtained fenugreek extract and baeknyeoncho extract, respectively, or may be obtained by extracting a mixture of fenugreek and baeknyeoncho.
상기 혼합추출물에 포함된 부채마 추출물과 백년초 추출물의 혼합비는 특별히 이에 제한되지 않으나, 일 예로서, 1:9 내지 9:1(w/w)로 혼합된 부채마와 백년초의 혼합물을 추출하여 수득할 수 있고, 다른 예로서, 부채마 추출물과 백년초 추출물을 1:9 내지 9:1(w/w)로 혼합하여 수득할 수도 있다.The mixing ratio of the extract of fenugreek extract and baeknyeoncho extract contained in the mixed extract is not particularly limited thereto, but as an example, obtained by extracting a mixture of fenugreek and baeknyeoncho mixed in 1:9 to 9:1 (w/w) As another example, it may be obtained by mixing the extract of fenugreek and baeknyeoncho extract at 1:9 to 9:1 (w/w).
본 발명의 용어, "추출물"이란, 목적하는 물질을 다양한 용매에 침지한 다음, 상온 또는 가온상태에서 일정시간 동안 추출하여 수득한 액상성분, 상기 액상성분으로부터 용매를 제거하여 수득한 고형분 등의 결과물을 의미한다. 뿐만 아니라, 상기 결과물에 더하여, 상기 결과물의 희석액, 이들의 농축액, 이들의 조정제물, 정제물 등을 모두 포함하는 것으로 포괄적으로 해석될 수 있다. As used herein, the term "extract" refers to a liquid component obtained by immersing a target substance in various solvents and then extracting it for a certain period of time at room temperature or in a heated state, and a product such as a solid obtained by removing the solvent from the liquid component. means In addition, in addition to the result, it can be comprehensively interpreted as including all of the diluent of the result, the concentrate thereof, the prepared product thereof, the purified product, and the like.
이에 따라, 본 발명에서 제공하는 부채마 추출물은 부채마의 꽃, 잎, 열매, 줄기, 뿌리, 껍질, 수액 등을 추출 처리하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함하는 것으로 해석될 수 있다. Accordingly, the extract provided by the present invention is an extract obtained by extracting flowers, leaves, fruits, stems, roots, peels, sap, etc. of the flower, leaves, fruits, stems, roots, peels, sap, etc. It may be interpreted to include extracts of all formulations that can be formed using the extract itself and the extract, such as a prepared or purified product of the extract, or a mixture thereof.
본 발명에서 제공하는 백년초 추출물 역시 백년초의 꽃, 잎, 열매, 줄기, 뿌리, 껍질, 수액 등을 추출 처리하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함하는 것으로 해석될 수 있다. The extract provided by the present invention is also an extract obtained by extracting flowers, leaves, fruits, stems, roots, skins, sap, etc. of baeknyeoncho, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, and adjustment of the extract It may be construed to include extracts of all formulations that can be formed using the extract itself and the extract, such as a product or a purified product, or a mixture thereof.
본 발명의 부채마 추출물 및 백년초 추출물에 있어서, 상기 부채마 및 백년초를 추출하는 방법은 특별히 제한되지 않으며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 방법을 병용하여 수행될 수 있다.In the extract of the genus hemp and baeknyeoncho of the present invention, the method of extracting the fenugreek and baeknyeoncho is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, reflux extraction, and the like, and these may be performed alone or in combination of two or more methods.
본 발명에서 상기 추출에 사용되는 용매의 종류는 특별히 제한되지 않으며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물, 알코올 또는 이들의 혼합 용매 등을 들 수 있고, 이들은 단독으로 사용되거나 1종 이상 혼합하여 사용될 수 있으며, 구체적으로 물이 사용될 수 있다. 알코올을 용매로 사용하는 경우에는 구체적으로 탄소수 1 내지 4의 알코올을 사용할 수 있다.In the present invention, the type of solvent used for the extraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent include water, alcohol, or a mixed solvent thereof, and these may be used alone or in combination of one or more, and specifically water may be used. When alcohol is used as a solvent, an alcohol having 1 to 4 carbon atoms may be specifically used.
본 발명의 용어 "우울증(depression)"이란, 우울장애라고도 호칭되며, 의욕 저하와 우울감을 주요 증상으로 하여 다양한 인지 및 정신 신체적 증상을 일으켜 일상 기능의 저하를 가져오는 질환을 의미하는데, 감정, 생각, 신체 상태, 그리고 행동 등에 변화를 일으키는 심각한 질환으로 여겨지고 있다. 이러한 우울증을 치료하기 위하여, 세로토닌의 흡수를 억제하여 혈중 세로토닌의 농도를 높이는 제제를 개발하기 위한 연구가 진행되고 있는데, 대표적인 예로 플루옥세틴이 있다. 상기 플루옥세틴은 세로토닌과 함께 가바의 작용을 증진시켜 글루탐산의 활성을 저해하고 도파민, 노르에피네프린 등 다양한 신경전달물질의 작용을 억제함으로써 우울증을 개선시킨다고 알려져 있다.As used herein, the term "depression", also called depressive disorder, refers to a disease that causes a decrease in daily functions by causing various cognitive and psychophysical symptoms with a decrease in motivation and depression as the main symptoms. It is considered a serious disease that causes changes in , physical condition, and behavior. In order to treat such depression, research is being conducted to develop a drug that increases the concentration of serotonin in the blood by inhibiting the absorption of serotonin. A representative example is fluoxetine. The fluoxetine is known to improve depression by inhibiting the activity of glutamic acid by enhancing the action of GABA together with serotonin and inhibiting the action of various neurotransmitters such as dopamine and norepinephrine.
본 발명에서 사용되는 용어, "예방"이란, 본 발명에 따른 부채마 및 백년초의 혼합추출물을 우울증 증상이 나타나거나 또는 나타날 우려가 있는 개체에 투여하여 우울증의 발병을 억제하거나 지연시키는 모든 행위를 의미할 수 있다.As used in the present invention, the term "prevention" refers to any action that suppresses or delays the onset of depression by administering the mixed extract of fenugreek and basilica according to the present invention to an individual who has or is likely to show symptoms of depression. can do.
본 발명에서 사용되는 용어, "치료"란, 본 발명의 상기 조성물을 우울증 발병 의심 개체에 투여하여 우울증의 증세가 호전되도록 하거나 이롭게 되도록 하는 모든 행위를 의미할 수 있다.As used in the present invention, the term "treatment" may refer to any action for improving or benefiting symptoms of depression by administering the composition of the present invention to a subject suspected of having depression.
본 발명의 약학 조성물은 단일제제로도 사용할 수 있고, 공인된 우울증 치료 효과를 가진다고 알려진 약물을 추가로 포함하여 복합제제로 제조하여 사용할 수 있으며, 약제학적으로 허용되는 담체 또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 다용량 용기 내에 내입시켜 제조될 수 있다. The pharmaceutical composition of the present invention can be used as a single agent, and can be prepared and used as a combination formulation by additionally including a drug known to have an approved antidepressant effect, and a unit dose by formulation using a pharmaceutically acceptable carrier or excipient. It may be prepared in a form or by being introduced into a multi-dose container.
본 발명에서 사용되는 용어, "약학적으로 허용 가능한 담체"란 생물체를 자극하지 않으면서, 주입되는 화합물의 생물학적 활성 및 특성을 저해하지 않는 담체 또는 희석제를 의미할 수 있다. 본 발명에 사용 가능한 상기 담체의 종류는 특별히 제한되지 아니하며 당해 기술 분야에서 통상적으로 사용되고 약학적으로 허용되는 담체라면 어느 것이든 사용할 수 있고, 비자연적인 담체가 사용될 수 있다. 상기 담체의 비제한적인 예로는, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사 용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 등을 들 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.As used herein, the term “pharmaceutically acceptable carrier” may refer to a carrier or diluent that does not inhibit the biological activity and properties of the injected compound without irritating the organism. The type of carrier usable in the present invention is not particularly limited, and any carrier commonly used in the art and pharmaceutically acceptable may be used, and non-natural carriers may be used. Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and the like. These may be used alone or in mixture of two or more.
또한, 필요한 경우 항산화제, 완충액 및/또는 정균제 등 다른 통상의 첨가제를 첨가하여 사용할 수 있으며, 희석제, 분산제, 계면 활성제, 결합제, 윤활제 등을 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제 등으로 제제화하여 사용할 수 있다.In addition, if necessary, other conventional additives such as antioxidants, buffers and/or bacteriostats can be added and used, and diluents, dispersants, surfactants, binders, lubricants, etc. It can be used by formulating it into a dosage form, pill, capsule, granule, or tablet.
또한, 본 발명의 약학적 조성물은 약제학적으로 유효한 양의 부채마 및 백년초 혼합추출물을 포함할 수 있다. 본 발명에서 용어, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 일반적으로 0.001 내지 1000 mg/kg의 양, 바람직하게는 0.05 내지 200 mg/kg, 보다 바람직하게는 0.1 내지 100 mg/kg의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 그러나 본 발명의 목적상, 특정 환자에 대한 구체적인 치료적 유효량은 달성하고자 하는 반응의 종류와 정도, 경우에 따라 다른 제제가 사용되는지의 여부를 비롯한 구체적 조성물, 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다. In addition, the pharmaceutical composition of the present invention may include a pharmaceutically effective amount of a mixed extract of fenugreek and baeknyeoncho. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and is generally in an amount of 0.001 to 1000 mg/kg, preferably 0.05 to 200 mg/kg, more preferably 0.1 to 100 mg/kg, may be administered once to several times a day. However, for the purposes of the present invention, a specific therapeutically effective amount for a particular patient depends on the type and extent of the response to be achieved, the specific composition, including whether other agents are used, if necessary, the specific composition, the patient's age, weight, general health, It is preferable to apply differently depending on various factors including sex and diet, administration time, administration route and secretion rate of the composition, treatment period, drugs used together or concurrently with a specific composition, and similar factors well known in the pharmaceutical field.
본 발명의 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여할 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용을 유발하지 않으면서 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without causing side effects, and can be easily determined by those skilled in the art.
본 발명에서 사용된 용어, "투여"는 어떠한 적절한 방법으로 환자에게 본 발명의 약학적 조성물을 도입하는 것을 의미하며, 본 발명의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다.As used herein, the term "administration" means introducing the pharmaceutical composition of the present invention to a patient by any suitable method, and the administration route of the composition of the present invention is oral or parenteral as long as it can reach the target tissue. It can be administered through various routes.
본 발명에 따른 약학 조성물의 투여 방식은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방식에 따를 수 있다. 상기 투여 방식의 비제한적인 예로, 조성물을 경구 투여 또는 비경구 투여 방식으로 투여할 수 있다. 본 발명에 따른 약학 조성물은 목적하는 투여 방식에 따라 다양한 제형으로 제작될 수 있다. The method of administration of the pharmaceutical composition according to the present invention is not particularly limited, and may follow a method commonly used in the art. As a non-limiting example of the administration method, the composition may be administered by oral administration or parenteral administration. The pharmaceutical composition according to the present invention may be prepared in various dosage forms according to the desired administration method.
본 발명의 약학조성물의 투여량은 예를 들어, 본 발명의 약학 조성물을 사람을 포함하는 포유동물에 하루 동안 1 내지 20 ㎎/㎏, 보다 바람직하게는 1 내지 10㎎/㎏으로 투여할 수 있고, 본 발명의 조성물의 투여빈도는 특별히 이에 제한되지 않으나, 1일 1회 투여하거나 또는 용량을 분할하여 수회 투여할 수 있다.The dosage of the pharmaceutical composition of the present invention may be, for example, 1 to 20 mg/kg, more preferably 1 to 10 mg/kg of the pharmaceutical composition of the present invention to mammals including humans for one day. , The frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or administered several times by dividing the dose.
본 발명의 다른 실시양태는 부채마와 백년초의 혼합추출물을 우울증 증상이 나타나거나 또는 나타날 우려가 있는 개체에 투여하는 단계를 포함하는 우울증의 예방 또는 치료 방법을 제공한다. Another embodiment of the present invention provides a method for preventing or treating depression, comprising administering a mixed extract of fenugreek and baeknyeoncho to an individual who has symptoms of depression or is likely to appear.
본 발명의 용어 "부채마", "백년초" 및 "우울증"에 대하여는 상기 정의한 바와 동일하다.The terms "buchaema", "baeknyeoncho" and "depression" of the present invention are the same as defined above.
본 발명에서 사용되는 용어, "개체"란, 우울증 증상이 나타나거나 또는 나타날 우려가 있는 인간을 포함한 모든 동물을 의미할 수 있다. 상기 동물은 인간뿐만 아니라 이와 유사한 증상의 치료를 필요로 하는 소, 말, 양, 돼지, 염소, 낙타, 영양, 개, 고양이 등의 포유동물일 수 있으나, 이에 제한되지는 않는다.As used herein, the term "individual" may refer to any animal, including humans, that exhibits or is likely to exhibit symptoms of depression. The animal may be a mammal, such as a cow, a horse, a sheep, a pig, a goat, a camel, an antelope, a dog, a cat, and the like, in need of treatment for symptoms similar to those of a human, but is not limited thereto.
본 발명의 상기 예방 또는 치료 방법은 구체적으로, 우울증 증상이 나타나거나 또는 나타날 우려가 있는 개체에 상기 조성물을 약학적으로 유효한 양으로 투여하는 단계를 포함할 수 있다.Specifically, the prevention or treatment method of the present invention may include the step of administering the composition in a pharmaceutically effective amount to an individual who has or is likely to show symptoms of depression.
본 발명에서 사용된 용어, "투여"는 어떠한 적절한 방법으로 우울증 증상이 나타나거나 또는 나타날 우려가 있는 개체에게 본 발명의 약학적 조성물을 도입하는 것을 의미하며, 본 발명의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다.As used herein, the term "administration" refers to introducing the pharmaceutical composition of the present invention to an individual who has or is likely to exhibit depression symptoms by any suitable method, and the route of administration of the composition of the present invention is the target tissue. It can be administered through various routes, either oral or parenteral, as long as it can be reached.
본 발명의 또 다른 실시양태는 부채마와 백년초의 혼합추출물을 포함하는, 우울증 예방 또는 개선용 식품 조성물을 제공한다. Another embodiment of the present invention provides a food composition for preventing or improving depression, comprising a mixed extract of fenugreek and baeknyeoncho.
본 발명의 용어 "부채마", "백년초" 및 "우울증"에 대하여는 상기 정의한 바와 동일하다.The terms "buchaema", "baeknyeoncho" and "depression" of the present invention are the same as defined above.
상기 부채마와 백년초는 천연 물질로서 오랫동안 사용되어 안정성이 입증되었으므로, 상식할 수 있으면서도 우울증 증상의 예방 또는 개선을 도모할 수 있는 식품의 형태로 제조되어 섭취할 수 있다.Since the fenugreek and baeknyeoncho has been used for a long time as a natural material and proven to be stable, it can be prepared and consumed in the form of food that can prevent or improve depression symptoms while being common sense.
본 발명의 식품 조성물은 식품의 제조에 사용되는 다양한 성분을 함께 건강기능식품을 제조하는데 사용될 수 있다.The food composition of the present invention can be used to prepare a health functional food together with various ingredients used in the preparation of food.
건강기능식품(functional food)이란, 특정보건용 식품(food for special health use, FoSHU)와 동일한 용어로, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미하는데, 상기 식품은 우울증의 예방 또는 개선에 유용한 효과를 얻기 위하여 정제, 캡슐, 분말, 과립, 액상, 환 등의 다양한 형태로 제조될 수 있다.Functional food is the same term as food for special health use (FoSHU), and it refers to foods with high medical and medical effects that are processed to efficiently exhibit bioregulatory functions in addition to nutritional supply. , The food may be prepared in various forms such as tablets, capsules, powders, granules, liquids, pills, etc. in order to obtain a useful effect in the prevention or improvement of depression.
상기 부채마와 백년초의 혼합추출물이 포함된 건강기능식품의 종류는 특별히 이에 제한되지 않으나, 일 예로서, 각종 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있다. The type of health functional food containing the mixed extract of fenugreek and baeknyeoncho is not particularly limited thereto, but as an example, there are various beverages, gum, tea, vitamin complexes, health supplements, and the like.
상기 식품 조성물에는 우울증 증상의 예방 또는 개선 효과에 방해가 되지 않는 다른 성분을 추가할 수 있으며, 그 종류는 특별히 제한되지 않는다. 예를 들어, 통상의 식품과 같이 여러 가지 생약 추출물, 식품학적으로 허용가능한 식품보조첨가제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.Other ingredients that do not interfere with the prevention or improvement effect of depression symptoms may be added to the food composition, and the type thereof is not particularly limited. For example, it may contain various herbal extracts, food-logically acceptable food supplements or natural carbohydrates as additional ingredients, such as conventional foods.
상기 식품보조첨가제는 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 예를 들어 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 그 종류가 제한되는 것은 아니다.The food supplement additives are added to the preparation of health functional foods of each formulation, and those skilled in the art may appropriately select and use them. For example, various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavoring agents such as flavoring agents, coloring agents and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents , stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like, but the types are not limited by the above examples.
이때, 상기 식품에 포함되는 추출물의 함량은 특별히 이에 제한되지 않으나, 식품 조성물의 총 중량에 대하여 0.01 내지 100 중량%, 보다 바람직하게는 1 내지 80 중량%로 포함될 수 있다. At this time, the content of the extract contained in the food is not particularly limited thereto, but may be included in an amount of 0.01 to 100% by weight, more preferably 1 to 80% by weight, based on the total weight of the food composition.
식품이 음료인 경우에는 100㎖를 기준으로 1 내지 30g, 바람직하게는 3 내지 20g의 비율로 포함될 수 있다. 또한, 상기 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예를 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용된다.When the food is a beverage, it may be included in a ratio of 1 to 30 g, preferably 3 to 20 g, based on 100 ml. In addition, the composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, vision, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, and the like may be included. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu). In addition, it may include amino acids such as lysine, tryptophan, cysteine, and valine. In addition, preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder and high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene ( BHT), etc.), colorant (tar pigment, etc.), color developer (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG sodium glutamate, etc.), sweetener (dulcin, cyclmate, saccharin, sodium, etc.) Food additives such as flavorings (vanillin, lactones, etc.), expanding agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (flavors), film agents, gum base agents, foam suppressants, solvents, and improving agents ) can be added. The additive is selected according to the type of food and used in an appropriate amount.
본 발명의 건강기능성 식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조 시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어날 수 있다.The health functional food of the present invention can be prepared by a method commonly used in the art, and during the manufacture, it can be prepared by adding raw materials and components commonly added in the art. In addition, unlike general drugs, food is used as a raw material, so there are no side effects that may occur when taking the drug for a long time, and it can be excellent in portability.
본 발명의 또 다른 실시양태는 부채마와 백년초의 혼합추출물을 포함하는, 우울증 예방 또는 개선용 사료 조성물을 제공한다. Another embodiment of the present invention provides a feed composition for preventing or improving depression, comprising a mixed extract of fenugreek and baeknyeoncho.
본 발명의 용어 "부채마", "백년초" 및 "우울증"에 대하여는 상기 정의한 바와 동일하다.The terms "buchaema", "baeknyeoncho" and "depression" of the present invention are the same as defined above.
상기 사료 조성물은 사료 첨가제를 포함할 수 있다. 본 발명의 사료첨가제는 사료관리법상의 보조사료에 해당한다.The feed composition may include a feed additive. The feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act.
본 발명에서 용어, "사료"는 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한끼식의 성분을 의미할 수 있다.As used herein, the term “feed” may mean any natural or artificial diet, one-meal meal, etc. or a component of the one-meal meal for or suitable for animal eating, ingestion, and digestion.
상기 사료의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용되는 사료를 사용할 수 있다. 상기 사료의 비제한적인 예로는, 곡물류, 근과류, 식품 가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류 또는 곡물 부산물류 등과 같은 식물성 사료; 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질류, 동물성 플랑크톤류 또는 음식물 등과 같은 동물성 사료를 들 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The type of feed is not particularly limited, and feed commonly used in the art may be used. Non-limiting examples of the feed include plant feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, gourds or grain by-products; and animal feeds such as proteins, inorganic materials, oils and fats, minerals, oils and fats, single cell proteins, zooplankton or food. These may be used alone or in mixture of two or more.
본 발명에서 제공하는 부채마와 백년초의 혼합추출물을 포함하는 조성물은 우울증에 의한 부동자세 유지시간을 감소시키고, 혈중 세로토닌의 수준을 증가시킬 수 있으며, 혈중 코르티코스테론의 수준을 감소시킬 수 있으므로, 우울증 증상의 개선에 널리 활용될 수 있을 것이다.The composition comprising a mixed extract of fenugreek and baeknyeoncho provided in the present invention can reduce the immobility maintenance time due to depression, increase the level of serotonin in the blood, and reduce the level of corticosterone in the blood, It can be widely used to improve the symptoms of depression.
도 1은 부채마와 백년초의 혼합추출물의 투여에 따른, 우울증 동물모델의 부동자세 유지시간 변화를 측정한 결과를 나타내는 그래프이다.
도 2는 부채마와 백년초의 혼합추출물의 투여에 따른, 우울증 동물모델의 혈중 세로토닌 수준의 변화를 측정한 결과를 나타내는 그래프이다.
도 3은 부채마와 백년초의 혼합추출물의 투여에 따른, 우울증 동물모델의 혈중 코르티코스테론 수준의 변화를 측정한 결과를 나타내는 그래프이다.
도 4는 부채마와 백년초의 혼합추출물을 투여한 난소적출 마우스 모델의 혈중 세로토닌 함량의 변화를 측정한 결과를 나타내는 그래프이다.1 is a graph showing the results of measuring the change in immobility posture maintenance time of an animal model of depression according to the administration of a mixed extract of fenugreek and baeknyeoncho.
2 is a graph showing the results of measuring changes in blood serotonin levels in an animal model of depression according to the administration of a mixed extract of fenugreek and baeknyeoncho.
3 is a graph showing the results of measuring changes in blood corticosterone level in an animal model of depression according to the administration of a mixed extract of fenugreek and baeknyeoncho.
4 is a graph showing the results of measuring the change in blood serotonin content in an ovariectomized mouse model administered with a mixed extract of fenugreek and baeknyeoncho.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예 1: 우울증 동물모델 확립Example 1: Establishment of an animal model of depression
먼저, 부채마 및 백년초(손바닥 선인장)의 혼합추출물의 우울증 개선 효능을 확인하기 위하여, 구속 스트레스를 이용한 우울증이 유발된 동물 모델을 제작하였다.First, in order to confirm the depression improvement efficacy of the mixed extract of fenugreek and baeknyeoncho (palm cactus), an animal model inducing depression using restraint stress was prepared.
대략적으로, 온도 및 습도가 관리되는 SPF(specific pathogen free)등급의 사육실에서 C57BL/6 6주령의 마우스를 입고 후 일주일간 순화를 실시하였다. 일주일간 순화된7주령의 마우스를 우울증을 유도하기 위하여 매일 4시간씩 억제스트레스 (신체구금 스트레스)를 21일 동안 지속하였다.Roughly, C57BL/6 6-week-old mice were put in a breeding room of SPF (specific pathogen free) grade in which temperature and humidity were managed, and then acclimatized for a week. In order to induce depression in 7-week-old mice acclimatized for one week, inhibitory stress (body detention stress) was continued for 21 days every day for 4 hours.
또한, 부채마 및 백년초의 혼합추출물을 다음과 같이 제조하였다.In addition, a mixed extract of fenugreek and baeknyeoncho was prepared as follows.
대략적으로, 백년초와 부채마를 각각 환류추출기를 이용하여 70% 에탄올로 75 내지 80℃ 에서 2시간 동안 추출하여 각각의 추출물을 수득하였다. 수득한 각 추출물을 회전증발기에 넣고, 원심분리하여(8,000 x g, 30분) 50%로 농축한 농축물을 수득하였다. 상기 수득한 농축물을 동결건조하여 각각의 백년초 추출물(KC) 및 부채마 추출물(B)를 수득하였다.Roughly, each extract was obtained by extracting baeknyeoncho and fenugreek for 2 hours at 75 to 80°C with 70% ethanol using a reflux extractor. Each extract obtained was placed in a rotary evaporator and centrifuged (8,000 x g, 30 minutes) to obtain a 50% concentrate. The obtained concentrate was freeze-dried to obtain each baeknyeoncho extract (KC) and fenugreek extract (B).
상기 수득한 백년초 추출물(KC) 및 부채마 추출물(B)을 동량(w/w) 혼합하여, 혼합추출물을 수득하였다.Equal amounts (w/w) of the obtained baeknyeoncho extract (KC) and fenugreek extract (B) were mixed to obtain a mixed extract.
상기 동물모델에 스트레스를 유발함과 동시에, KCB 추출물 투여군(부채마 및 백년초의 혼합추출물 200 mg/kg 투여군, S+KCB200) 또는 양성대조군(우울증 치료제인 Fluoxetine 20 mg/kg 투여군, S+F20)이 첨가된 식이를 3주간 급이시키면서, 주 2회 체중 및 식이의 양을 측정하여 해당 모델의 건강 상태와 각 해당 사료를 섭취가 올바르게 진행되는지 확인하였다. 이때, 정상군으로는 스트레스를 유발하지 않은 마우스를 사용하고, 스트레스 유발군으로는 스트레스를 유발한 마우스를 사용하였다.At the same time as inducing stress in the animal model, a group administered with KCB extract (200 mg/kg of mixed extract of P. chama and basilica, S+KCB200) or a positive control group (a group administered with fluoxetine 20 mg/kg, a treatment for depression, S+F20) While feeding this added diet for 3 weeks, the body weight and the amount of food were measured twice a week to confirm the health status of the model and whether the intake of each corresponding feed was performed correctly. In this case, mice that did not induce stress were used as the normal group, and mice induced with stress were used as the stress-induced group.
실시예 2: 동물부동시간 측정Example 2: Measurement of animal immobility time
상기 실시예 1에서 제작한 각 마우스(정상군, 스트레스 유발군, 양성대조군 및 KCB 추출물 투여군)를 대상으로 표준화된 검사법인 FST(절망행동검사)를 수행하였다. The standardized test method FST (Despair Behavior Test) was performed on each mouse (normal group, stress-induced group, positive control group, and KCB extract administration group) prepared in Example 1 above.
대략적으로, 투명 아크릴로 제작된 원통의 Water bath에 25±1℃의 물을 넣고 상기 각 마우스를 꼬리가 바닥에 닿지 않을 높이에 빠뜨린 다음 10분 동안 강제로 예비 수영을 시켰다. 24시간 후에 5분 동안 같은 환경에서 수영을 시키면서 부동자세를 유지하는 시간을 측정하였다. 측정은 처음 1분간은 적응시키고 4분 동안 이루어졌으며, 비디오카메라로 녹화한 뒤, Video tracking software (SMART 3.0, Panlab, Spai)를 이용하여 수중에서 실험동물의 전체적인 움직임을 분석하였다(도 1). Roughly, 25±1° C. of water was put in a cylindrical water bath made of transparent acrylic, and each mouse was placed at a height where the tail would not touch the floor, and then forced to pre-swim for 10 minutes. After 24 hours, the time to maintain an immobile position while swimming in the same environment for 5 minutes was measured. Measurements were made for 4 minutes after acclimatization for the first 1 minute, and after recording with a video camera, the overall movement of the experimental animal in water was analyzed using video tracking software (SMART 3.0, Panlab, Spai) (FIG. 1).
도 1은 부채마와 백년초의 혼합추출물의 투여에 따른, 우울증 동물모델의 부동자세 유지시간 변화를 측정한 결과를 나타내는 그래프이다.1 is a graph showing the results of measuring the change in immobility posture maintenance time of an animal model of depression according to the administration of a mixed extract of fenugreek and baeknyeoncho.
도 1에서 보듯이, 정상군에 비하여 스트레스 유발군에서는 부동자세 유지시간이 증가하였으나, 스트레스를 유발한 후 부채마 및 백년초의 혼합추출물 투여한 경우에는 부동자세 유지시간이 정상군의 수준으로 감소되었는데, 이러한 효과는 우울증 치료제로 알려진 Fluoxetine을 투여한 양성대조군과 동일한 수준의 효과임을 확인하였다.As shown in FIG. 1 , the immobility maintenance time was increased in the stress-induced group compared to the normal group, but when the mixed extract of fenugreek and baeknyeoncho was administered after inducing stress, the immobility maintenance time was reduced to the level of the normal group. , It was confirmed that this effect was at the same level as the positive control group administered with Fluoxetine, which is known as an antidepressant.
실시예 3: 세로토닌 혈중함량 측정Example 3: Measurement of serotonin blood content
상기 실시예 1에서 제작한 각 마우스(정상군, 스트레스 유발군, 양성대조군 및 KCB 추출물 투여군)로부터 채혈한 후, 채혈된 혈액에 포함된 혈중 세로토닌의 농도를 측정한 후, 상호 비교하였다(도 2). 이때, 채혈 및 혈중 세로토닌의 농도는 다음의 방법으로 수행되었다:After collecting blood from each mouse (normal group, stress-induced group, positive control group, and KCB extract administration group) prepared in Example 1, the concentration of serotonin in the blood was measured and then compared with each other (FIG. 2). ). At this time, blood collection and blood serotonin concentration were performed in the following way:
각 마우스를 아르베틴( Avertin)으로 마취하여 복대동맥에서 전혈을 채취하고; 채혈한 전혈은 SST 튜브에 옮긴 후 충분히 섬유소에 의한 혈액응고가 진행되면 4,000rpm에서 10분 동안 원심분리하고, 적혈구의 용혈 등에 주의하여 상층액인 혈청을 채취하였으며; 채취된 각 혈정을 세로토닌 측정키트(Abcam사의 Serotonin ELISA Kit; ab133053)에 적용하여 각 혈청에 포함된 세로토닌의 함량을 측정하고 이를 비교하였다).Whole blood was collected from the abdominal aorta by anesthetizing each mouse with Avertin; After the collected whole blood was transferred to the SST tube, when the blood coagulation by fibrin had sufficiently progressed, it was centrifuged at 4,000 rpm for 10 minutes, and the supernatant serum was collected, paying attention to the hemolysis of red blood cells; Each collected blood serum was applied to a serotonin measuring kit (Serotonin ELISA Kit of Abcam; ab133053) to measure the serotonin content in each serum and compared).
도 2는 부채마와 백년초의 혼합추출물의 투여에 따른, 우울증 동물모델의 혈중 세로토닌 수준의 변화를 측정한 결과를 나타내는 그래프이다.Figure 2 is a graph showing the results of measuring the change in blood serotonin level in an animal model of depression according to the administration of a mixed extract of fenugreek and baeknyeoncho.
도 2에서 보듯이, 정상군에 비하여 스트레스 유발군에서는 혈중 세로토닌의 농도가 현저히 감소되었으나, 스트레스를 유발한 후 부채마 및 백년초의 혼합추출물 투여한 경우에는 혈중 세로토닌의 농도가 현저히 증가하여 정상군의 수준보다도 높은 수준을 나타내었는데, 이러한 수준은 우울증 치료제로 알려진 Fluoxetine을 투여한 양성대조군의 혈중 세로토닌의 농도보다는 낮은 수준임을 확인하였다.As shown in FIG. 2 , the concentration of serotonin in the blood was significantly decreased in the stress-induced group compared to the normal group, but when the mixed extract of fenugreek and baeknyeoncho was administered after inducing stress, the concentration of serotonin in the blood was significantly increased, resulting in a significant increase in the concentration of serotonin in the normal group. The level was higher than the level, and it was confirmed that this level was lower than the concentration of serotonin in the blood of the positive control group to which Fluoxetine, known as an antidepressant, was administered.
실시예 4: 코르티코스테론 혈중함량 측정Example 4: Measurement of corticosterone blood content
상기 실시예 1에서 제작한 각 마우스(정상군, 스트레스 유발군, 양성대조군 및 KCB 추출물 투여군)로부터 채혈한 후, 채혈된 혈액에 포함된 혈중 코르티코스테론의 농도를 측정한 후, 상호 비교하였다(도 3). 이때, 채혈 및 혈중 코르티코스테론의 농도는, 세로토닌 측정키트 대신에 코르티코스테론 측정키트를 사용하는 것을 제외하고는, 상기 실시예 3의 방법과 유사한 방법을 사용하여 수행하였다.After collecting blood from each mouse (normal group, stress-induced group, positive control group, and KCB extract administration group) prepared in Example 1, the concentration of corticosterone in the blood was measured and then compared with each other ( Fig. 3). At this time, blood collection and blood corticosterone concentrations were performed using a method similar to that of Example 3, except that a corticosterone measurement kit was used instead of the serotonin measurement kit.
도 3은 부채마와 백년초의 혼합추출물의 투여에 따른, 우울증 동물모델의 혈중 코르티코스테론 수준의 변화를 측정한 결과를 나타내는 그래프이다.3 is a graph showing the results of measuring changes in blood corticosterone levels in an animal model of depression according to the administration of a mixed extract of fenugreek and baeknyeoncho.
도 3에서 보듯이, 정상군에 비하여 스트레스 유발군에서는 혈중 코르티코스테론 수준이 증가하였으나, 스트레스를 유발한 후 부채마 및 백년초의 혼합추출물 투여한 경우에는 혈중 코르티코스테론 수준이 정상군의 수준보다도 낮은 수준으로 감소되었는데, 이러한 효과는 우울증 치료제로 알려진 Fluoxetine을 투여한 양성대조군과 동일한 수준의 효과임을 확인하였다.As shown in FIG. 3 , the level of corticosterone in the blood increased in the stress-induced group compared to the normal group, but when the mixed extract of fenugreek and baeknyeoncho was administered after inducing stress, the level of corticosterone in the blood was higher than that of the normal group. It was reduced to a low level, and this effect was confirmed to be the same level of effect as the positive control group administered with Fluoxetine, known as an antidepressant.
실시예 5: 난소적출 마우스의 혈중 세로토닌 농도 측정Example 5: Measurement of blood serotonin concentration in ovariectomized mice
상기 실시예 1 내지 4의 결과로부터, 구속 스트레스를 이용한 우울증이 유발된 동물 모델에서, 부채마 및 백년초의 혼합추출물이 우울증 증상을 개선시키는 효과를 나타냄을 확인하였으므로, 다른 우울증 모델인 난소적출 마우스를 사용할 경우에도 동일한 효과를 나타낼 수 있는지 확인하고자 하였다.From the results of Examples 1 to 4, it was confirmed that, in the animal model in which depression was induced using restraint stress, the mixed extract of fenugreek and basilica showed the effect of improving the symptoms of depression. It was tried to check whether the same effect can be exhibited even when used.
이를 위하여, 6주령 암컷 C57BL/6 마우스에서 난소를 적출하여 제작된 난소적출 마우스에 부채마와 백년초의 혼합추출물을 다양한 투여량으로 경구투여한 후, 이들 난소적출 마우스의 혈중 세로토닌의 농도를 비교하였다.To this end, the mixed extracts of fenugreek and baeknyeoncho were orally administered in various doses to ovariectomized mice prepared by excising ovaries from 6-week-old female C57BL/6 mice, and then the concentration of serotonin in the blood of these ovariectomized mice was compared. .
대략적으로, 6주령 암컷 C57BL/6 마우스(음성대조군, Vehicle); 난소적출 마우스(양성대조군, OVX); 난소적출 후 40㎍/㎖의 E2 호르몬을 투여한 난소적출 마우스(비교군, OVX+E2); 난소적출 후 100 mg/kg의 부채마와 백년초의 혼합추출물을 투여한 난소적출 마우스(실험군 1, OVX+KCB100); 난소적출 후 200 mg/kg의 부채마와 백년초의 혼합추출물을 투여한 난소적출 마우스(실험군 2, OVX+KCB200); 및 난소적출 후 400 mg/kg의 부채마와 백년초의 혼합추출물을 투여한 난소적출 마우스(실험군 3, OVX+KCB400)을 각각 준비하였다.Roughly, 6-week-old female C57BL/6 mice (negative control, Vehicle); ovariectomized mice (positive control, OVX); Ovariectomized mice administered 40 μg/ml of E2 hormone after ovariectomy (comparative group, OVX+E2); Ovariectomized mice administered 100 mg/kg of mixed extracts of fenugreek and baeknyeoncho after ovariectomy (Experimental group 1, OVX+KCB100); Ovariectomized mice administered 200 mg/kg of mixed extracts of fenugreek and baeknyeoncho after ovariectomy (Experimental group 2, OVX+KCB200); and ovariectomized mice (experimental group 3, OVX+KCB400) administered with a 400 mg/kg mixed extract of fenugreek and baeknyeoncho after ovariectomy were prepared.
이어, 상기 실시예 3의 방법으로 각 마우스로부터 채혈한 후, 채혈된 혈액에 포함된 혈중 세로토닌의 농도를 측정한 후, 상호 비교하였다(도 4).Then, after blood was collected from each mouse by the method of Example 3, the concentration of serotonin in the blood was measured and compared with each other (FIG. 4).
도 4는 부채마와 백년초의 혼합추출물을 투여한 난소적출 마우스 모델의 혈중 세로토닌 함량의 변화를 측정한 결과를 나타내는 그래프이다.Figure 4 is a graph showing the results of measuring the change in the blood serotonin content in an ovariectomized mouse model administered with a mixed extract of fenugreek and baeknyeoncho.
도 4에서 보듯이, 난소적출 마우스(양성대조군)에서는 정상 마우스(음성대조군)에 비하여 혈중 세로토닌의 함량이 감소되었으나, 난소적출 후 E2 호르몬을 투여한 경우(비교군)에는 정상 마우스(음성대조군)의 것과 유사한 수준으로 혈중 세로토닌의 함량이 회복됨을 확인하였다. 또한, 난소적출 후, 부채마와 백년초의 혼합추출물을 투여한 경우(실험군 1, 2 및 3)에는 정상 마우스(음성대조군) 보다도 현저히 증가된 혈중 세로토닌의 함량을 나타냈으며, 특이하게도 200 mg/kg의 부채마와 백년초의 혼합추출물을 투여한 경우(실험군 2)에 가장 높은 수준의 혈중 세로토닌의 함량을 나타냄을 확인하였다.As shown in FIG. 4 , in the ovariectomized mice (positive control group), the content of serotonin in the blood was decreased compared to the normal mice (negative control group), but when the E2 hormone was administered after ovariectomy (comparative group), normal mice (negative control group) It was confirmed that the content of serotonin in the blood was restored to a level similar to that of In addition, after ovariectomy, when the mixed extract of fenugreek and baeknyeoncho was administered (experimental groups 1, 2 and 3), the blood serotonin content was significantly increased compared to that of normal mice (negative control group), and specifically 200 mg/kg It was confirmed that the highest level of serotonin content in the blood was obtained when the mixed extract of P.
상기 결과로부터, 난소적출 마우스에서도, 구속 스트레스를 이용한 우울증이 유발된 동물 모델과 유사하게, 우울증으로 인하여 감소된 혈중 세로토닌의 농도를, 부채마와 백년초의 혼합추출물이 회복시키는 효과를 나타냄을 알 수 있었으므로, 상기 부채마와 백년초의 혼합추출물은 우울증의 예방, 개선 및 치료효과를 나타내는 것으로 분석되었다. From the above results, it can be seen that in ovariectomized mice, similar to the animal model in which depression using restraint stress was induced, the concentration of serotonin in the blood reduced due to depression was restored by the mixed extract of fenugreek and baeknyeoncho. Therefore, it was analyzed that the mixed extract of fenugreek and baeknyeoncho showed the prevention, improvement and treatment effects of depression.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the claims described below and their equivalents.
Claims (9)
A pharmaceutical composition for preventing or treating depression, comprising a mixed extract of an extract of Dioscorea nipponica Makino and baeknyeoncho ( Prickly Pear ) extract.
상기 부채마 추출물은 부채마를 물, 알코올 또는 이들의 혼합 용매로 추출하여 수득한 것인, 우울증 예방 또는 치료용 약학 조성물.
According to claim 1,
The fenugreek extract is a pharmaceutical composition for preventing or treating depression, which is obtained by extracting fenugreek extract with water, alcohol, or a mixed solvent thereof.
상기 백년초 추출물은 백년초를 물, 알코올 또는 이들의 혼합 용매로 추출하여 수득한 것인, 우울증 예방 또는 치료용 약학 조성물.
According to claim 1,
The baeknyeoncho extract is obtained by extracting baeknyeoncho with water, alcohol, or a mixed solvent thereof, a pharmaceutical composition for preventing or treating depression.
상기 혼합추출물은 부채마 추출물과 백년초 추출물을 1:9 내지 9:1(w/w)로 포함하는 것인, 우울증 예방 또는 치료용 약학 조성물.
According to claim 1,
The mixed extract is a pharmaceutical composition for preventing or treating depression, which includes the extract of fenugreek extract and baeknyeoncho extract from 1:9 to 9:1 (w/w).
상기 혼합추출물은 우울증에 의하여 유발되는 부동자세 유지 증상, 혈중 세로토닌의 수준감소 증상 및 혈중 코르티코스테론의 수준증가 증상을 개선시키는 효과를 나타내는 것인, 우울증 예방 또는 치료용 약학 조성물.
According to claim 1,
The mixed extract is a pharmaceutical composition for preventing or treating depression, which exhibits an effect of improving the symptoms of maintaining immobility caused by depression, reducing the level of serotonin in the blood, and increasing the level of corticosterone in the blood.
상기 우울증은 스트레스성 우울증 또는 갱년기성 우울증인 것인, 우울증 예방 또는 치료용 약학 조성물.
According to claim 1,
The depression is stress depression or menopausal depression, the pharmaceutical composition for preventing or treating depression.
A method for preventing or treating depression, comprising administering the pharmaceutical composition of any one of claims 1 to 6 to a subject other than a human who has or is likely to exhibit depressive symptoms.
Fan horse ( Dioscorea nipponica Makino ) extract and baeknyeoncho ( Prickly Pear ) A food composition for preventing or improving depression, comprising a mixed extract of the extract.
Fan horse ( Dioscorea nipponica Makino ) Extract and baeknyeoncho ( Prickly Pear ) A feed composition for preventing or improving depression, comprising a mixed extract of the extract.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190071744 | 2019-06-17 | ||
| KR20190071744 | 2019-06-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200144042A KR20200144042A (en) | 2020-12-28 |
| KR102323577B1 true KR102323577B1 (en) | 2021-11-09 |
Family
ID=74040075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190166801A KR102323577B1 (en) | 2019-06-17 | 2019-12-13 | Composition for preventing or treating depression comprising mixed extract of Dioscorea nipponica Makino and Prickly Pear |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102323577B1 (en) |
| WO (1) | WO2020256243A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530532A (en) | 2008-03-11 | 2009-09-16 | 北京凯瑞创新医药科技有限公司 | Oral pharmaceutical preparation of yam total sapogenin and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10350194B4 (en) * | 2003-10-28 | 2005-11-10 | Bioplanta Arzneimittel Gmbh | Use of extracts from Opuntia for the treatment of depressive moods and disorders |
| KR20070105643A (en) * | 2006-04-27 | 2007-10-31 | 주식회사 엠웰 | COMPOSITION FOR ACTIVATION OF beta;-ENDORPHIN COMPRISING EXTRACT OF OPUNTIA FICUS-INDICA VAR SABOTEN |
| KR101341692B1 (en) * | 2011-03-16 | 2013-12-20 | 동아에스티 주식회사 | Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy |
| KR101687271B1 (en) * | 2014-10-23 | 2016-12-19 | 한국 한의학 연구원 | A composition for preventing or treating menopausal disorder comprising Opuntia ficus-indica Mill extract and Dioscorea nipponica Makino extract |
-
2019
- 2019-12-13 WO PCT/KR2019/017671 patent/WO2020256243A1/en active Application Filing
- 2019-12-13 KR KR1020190166801A patent/KR102323577B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530532A (en) | 2008-03-11 | 2009-09-16 | 北京凯瑞创新医药科技有限公司 | Oral pharmaceutical preparation of yam total sapogenin and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 이상선 외. 수종의 생약추출물이 Monoamine Oxidase 활성에 미치는 영향. 생약학회지, 1998년, 제29권 제4호, pp. 271-276* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200144042A (en) | 2020-12-28 |
| WO2020256243A1 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120052138A1 (en) | Composition comprising green tea extract | |
| JP6529634B1 (en) | Amyloid β degradation efflux promoter | |
| US20210128664A1 (en) | Agent for Activating Astrocyte Glucose Metabolism | |
| JP6930037B2 (en) | Stroke preventive or therapeutic composition | |
| KR102348044B1 (en) | Composition for preventing, improving or treating burn out syndrome | |
| KR102072471B1 (en) | Composition for preventing and/or treating a neurodegenerative disease comprising extract or fraction of Aster koraiensis Nakai | |
| KR102323577B1 (en) | Composition for preventing or treating depression comprising mixed extract of Dioscorea nipponica Makino and Prickly Pear | |
| KR101775087B1 (en) | A composition for the prevention or treatment of stress or depression containing mulberrofuran G, sanggenon G and sanggenol A | |
| CN116077474A (en) | Methods and compositions for increasing energy expenditure using cinnamaldehyde | |
| JP7106340B2 (en) | Blood-brain barrier protectant | |
| JP6499787B1 (en) | Arc expression promoter | |
| KR102120376B1 (en) | Composition for preventing and/or treating a degenerative brain disease comprising as an active ingredient an extract of Cimicifuga dahurica, a fraction thereof, or a compound derived from Cimicifuga dahurica | |
| KR101221623B1 (en) | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of root of vitis | |
| KR101241455B1 (en) | Bean curd having hypotensive effect | |
| JP2020169123A (en) | Hotflash improver | |
| KR102240706B1 (en) | A composition for sleep induction comprising Passiflora incarnata extract | |
| JP2020025503A (en) | Eye-aging preventive agent and eye-aging prevention supplement | |
| KR102338347B1 (en) | Composition for preventing or treating tic disorders comprising an extract of Rehmannia glutinosa as an active ingredient | |
| KR102282883B1 (en) | Composition for preventing and/or treating a degenerative brain disease comprising as an active ingredient an extract of Cimicifuga dahurica, a fraction thereof, or a compound derived from Cimicifuga dahurica | |
| TWI604840B (en) | Fat loss weight loss composition | |
| WO2017130638A1 (en) | Agent for activating astrocyte glucose metabolism | |
| KR20210136854A (en) | Composition for preventing or treating cognitive impairment comprising extract of iris lactea | |
| KR101674224B1 (en) | Composition comprising the extracts of Hericium erinaceus for preventing or treating brain disease | |
| KR20210099911A (en) | Pharmaceutical composition for preventing and treating neurological diseases comprising gossypol or derivatives thereof as an active ingredient | |
| EA034370B1 (en) | Oral composition for improving systemic symptoms including sensitivity to cold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |